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half-cycle correction method provided more accurate results than calculations with-
out any kind of half-cycle correction with the exception of one set of input param-
eters. ConClusions: Based on our model the most accurate method for half-cycle 
correction is Simpson’s method as in most cases it was the closest to real data. It is 
important to note that with a few exceptions even the standard method’s results were 
more accurate than in cases where no half-cycle correction was applied.
PRM77
APPlicAtion of A Model of decision BAsed on fuzzy logic to 
PhARMAcoeconoMics: tReAtMent of cRohn’s diseAse With Antitnf in 
out of lABel use
Alonso Herreros J.M.1, González-Cuello A.2
1HOSPITAL LOS ARCOS MAR MENOR, SAN JAVIER (MURCIA), Spain, 2Murcia University, 
MURCIA, Spain
objeCtives: We present a model decision based on fuzzy logic, and apply to off 
label use of antiTNF in Crohn’s disease (CD) (Infliximab (IFB) 10 mg/kg/8 weeks, 
adalimumab (ADA) 80mg/2 weeks,. Certolizumab (CZB) 200mg/2weeks). The term 
“fuzzy logic” (FL) was introduced in 1965 by LAZadeh. Compared to traditional logic, 
FL variables may have a truth value in degree. FL has been applied to many fields, from 
economic analysis, to artificial intelligence. However it has not been applied so far to 
pharmacoeconomics. Methods: According to a decision analysis model based on FL 
four fuzzy variables that affect the choice of treatment are defined: treatment success 
(expressed as a probability), cost of success, cost of failure (expressed as inverses), 
and other conditions about the cost (negotiation, handling of drugs...). Based on the 
value of these fuzzy variables, three linguistic variables (High, Medium, Low) are 
defined to expressing convenience of choice. The combination of the three possible 
values for each of the variables gives us 81 possible decision rules, so that the (HHHH) 
would be the most favorable option and (LLLL) the more unfavorable. So a new fuzzy 
variable called “ranking” is established for classifying these options with 7 possible 
values (Very-unfavorable, unfavorable, slightly-unfavorable, neutral, slightly-favorable, 
favorable, very-favorable). The value of the fuzzy variables for antiTNF at 52 weeks 
of treatment, were established based recent meta-analysis and reviews. Results: 
The matrices obtained and corresponding decision rules were: for IFB (0.65, 6.3 10-5, 
-1.17 10-4, 0.075) / (MMML); For ADA (0.41, 9.21 10-5, 6.4 10-5, 0.075) / (MMML); for CZB 
(0.52, 1.30 10-4 1.5 10-4 0.075) / (MHHB). Thus the CZB would be the “slightly-favorable” 
option, versus IFB and ADA (unfavorables). ConClusions: It possible to apply meth-
ods of “FL” to pharmacoeconomic studies According to the model, Certolizumab would 
be a most favorable choice in off-label use for CD.
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objeCtives: Since the introduction of the orphan drugs in Europe, it has been sug-
gested that the general method of appraising drugs for reimbursement is not nec-
essarily suitable for orphan drugs. The National Institute for Health and Clinical 
Excellence indicated that several criteria other than cost and efficacy could be 
considered in reimbursement decisions for orphan drugs. The aim of this study 
was to apply a MCDA framework that was proposed by Hughes-Wilson et al (2012) 
to a range of orphan drugs in different diseases to test the correlation between 
drug price and aggregated MCDA scores for each product. Methods: A MCDA 
framework was developed using the nine criteria suggested by Hughes-Wilson 
et al. A supplementary literature review was conducted to identify other attrib-
utes described in the application of MCDA in rare diseases. A numerical scoring 
system on a scale of one to three was developed for each criterion. Correlations 
between the average annual cost of the drugs and aggregate MCDA scores were 
tested and plotted graphically. Different weightings for each of the attributes were 
also tested. A further analysis was conducted to test the impact of including the 
drug cost as an attribute in the aggregate index scores. Results: The literature 
review identified further commonly cited criteria: ‘convenience of administra-
tion’, ‘age of the target population’, ‘quality of life’, and ‘drug innovation’ that 
were added to the aggregate index scores. In the drugs studied, the R2was 0.808 
and 0.704 when costs were included and not included, respectively. The standard 
error of the slope varied from 7711.9 to 11413.3 when costs were included and not 
included, respectively. ConClusions: This quantitative study provided insight 
into using MCDA and its relationship to annual costs. Further work should explore 
the potential for therapy-specific MCDAs and how to inform value-based pricing 
assessment.
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bACkgRound: Modelers and reimbursement decision makers could both profit 
from a more systematic reporting of the efforts to validate health-economic (HE) 
models. objeCtives: Development of a tool to systematically report validation 
efforts of HE decision models and their outcomes. Methods: A gross list of model 
validation techniques was collected using a literature review, including sources 
outside the HE field. A panel then selected the most important items. Based on 
the Delphi method, the panel members could score items in three e-mail rounds. 
Participants were HE modelling experts, covering various nationalities and work 
environments. They could comment on relevance, feasibility and formulation of 
the items and received feedback on comments from others. This resulted in a draft 
tool of selected items, which was tested and improved in two further rounds. In 
population are 18.5% for males and 9.8% for females. ConClusions: Random sam-
pling from patient level data provided the best approximation of actual NHANES 
population predicted CVD rates. The cholesky decomposition approach was slightly 
limited since only continuous variables could be utilized which could explain the 
deviation from the population predicted CVD rates. Independent sampling under-
estimated the mean risk by ~20%, an interesting finding as many individual simula-
tion models created patients with this approach. Researchers should be cautious 
in their use of summary statistics when populating individual simulation models.
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objeCtives: We have developed a model to evaluate type-2 diabetes prevention 
interventions. We aimed to validate this model against external data to test the accu-
racy of model predictions. MethodsAn individual patient simulation was developed 
to predict longitudinal trajectories of HbA1c, 2-hr glucose, FPG, BMI, systolic blood 
pressure, total cholesterol and HDL cholesterol based on statistical analyses of the 
Whitehall II longitudinal cohort. Criteria for diabetes diagnosis were flexibly speci-
fied. Cardiovascular events were estimated from the QRISK2 algorithm. Microvascular 
complications of diabetes were estimated from the UKPDS outcomes model. Several 
validations were performed to compare model outcomes with reported data from 
external sources. We assessed the predicted diabetes incidence using data from the 
EPIC Norfolk cohort. Data from the Health Survey for England (HSE) 2003 cohort was 
simulated for eight years to compare predicted disease incidence and metabolic 
distributions with HSE 2011 data. We compared microvascular, cardiovascular and 
mortality outcomes in a diabetic population with those observed in the UKPDS. We 
assessed the performance of the model in predicting the results of the ADDITION trial 
for diabetes screening. Results: We found that the model overestimated three-year 
incidence of diabetes, particularly in high risk (HbA1c> 6.0) individuals, but underesti-
mated diabetes incidence in medium risk individuals (HbA1c 5.5-5.9) compared with 
the EPIC-Norfolk data. Predictions from HSE 2003 were fairly accurate. Predictions 
for microvascular events were similar to the UKPDS, but cardiovascular disease and 
mortality were slightly under-predicted. The model replicated the non-significant 
difference seen between control and intervention arms of the ADDITION trial, but 
overestimated total mortality and cardiovascular disease. ConClusions: The SPHR 
Diabetes model appears to be fairly accurate at predicting external data, but has 
a tendency to overestimate mortality rates in a newly diagnosed diabetic cohort, 
and underestimate cardiovascular disease and mortality compared with the UKPDS.
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objeCtives: Often in cost-effectiveness analysis (CEA) of oncologic drugs, survival 
data from a randomized controlled trial are extrapolated to a lifetime horizon using 
parametric regression techniques. To capture parameter uncertainty in the analysis, 
regression parameters along with other model parameters are varied in probabilistic 
sensitivity analysis. However, structural uncertainty in the choice of regression 
model is rarely investigated. This study discusses the use of model averaging and 
provides an example to address structural uncertainty in CEA. Methods: Using a 
cohort partition model, the numbers of patients in “progression-free”, “progressed”, 
and “dead” health states were calculated directly from progression-free survival 
(PFS) and overall survival (OS) curves. Weibull, exponential, lognormal, log-logistic, 
generalized gamma, and Gompertz parametric models were used to extrapolated 
these curves to a lifetime horizon. Total costs, life year (LY), and quality adjusted 
life year (QALY) for each regression model were estimated. Weighted results across 
all models were calculated, based on weights that were derived from Akaike’s or 
Bayesian Information Criterion (AIC or BIC) parameters. Results: Evaluating 
solely on BIC values, the lognormal distribution was identified as the best model 
for both survival curves. This resulted in the lowest observed ICERs. When model 
selection was based on considerations involving the log-cumulative hazard plots, 
clinical plausibility, and AIC/ BIC for each distribution, the Weibull distribution was 
selected for both curves, resulting in a 29% and 27% increase in the ICER for QALY 
and LY, respectively. Similar increases were observed when model averaging was 
applied using BIC-derived weights. In this case, model averaging produced results 
that were similar to those where model selection was based on multiple criteria.  
ConClusions: Choice of parametric models often has the biggest impact on the 
outcomes in CEAs in oncology. Model averaging takes into account the structural 
uncertainty surrounding the choice of parametric models.
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objeCtives: To compare three different half-cycle correction methods and their 
effect on the final results of Markov models. Methods: To assess the relative per-
formance of the alternatives to the standard half-cycle correction we constructed a 
5-state Markov model where the courses of the number of patients in health states 
follow different shapes to represent the most likely cases in modelling practise. We 
applied three different correction methods (standard half-cycle correction, Simpson’s 
method and using the mid-cycle values) and we also looked at the results without any 
correction and with different numbers of Markov cycles. We conducted a sensitivity 
analysis by changing the input parameters of our model. In total we examined 80 
cases. Results: In our Markov model Simpson’s method provided the most accurate 
results where the difference from real data was less than 0.1% in 67 of the 80 cases. 
The second most accurate method was using the mid-cycle values. The standard 
